Recent Finacing
Recent Raise
TargeGen develops vascular-targeted therapeutics that inhibit abnormal blood-vessel growth for indications including age-related macular degeneration, cancer, and heart disease; its TG100801 completed a phase I AMD safety trial.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
